Subject(s)
Clinical Medicine/trends , Physician's Role , Clinical Medicine/standards , Forecasting , HumansSubject(s)
Societies, Medical/trends , Education, Medical, Continuing , Forecasting , Humans , United StatesSubject(s)
Awards and Prizes , Fellowships and Scholarships , Schools, Medical , Training Support , Faculty, Medical , Humans , Physicians , Societies, MedicalSubject(s)
Alzheimer Disease/diagnosis , Dementia/diagnosis , Geriatric Assessment , Mental Disorders/diagnosis , Patient Care Team , Aged , Aged, 80 and over , Alzheimer Disease/rehabilitation , Combined Modality Therapy , Dementia/rehabilitation , Female , Humans , Male , Mental Disorders/rehabilitation , Middle Aged , Patient Admission , Psychiatric Status Rating ScalesSubject(s)
Antidepressive Agents/administration & dosage , Antipsychotic Agents/administration & dosage , Hypnotics and Sedatives/administration & dosage , Aged , Antidepressive Agents/pharmacokinetics , Antidepressive Agents/pharmacology , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/pharmacology , Humans , Hypnotics and Sedatives/pharmacokinetics , Hypnotics and Sedatives/pharmacologyABSTRACT
Because of the unstructured life-style of most narcotic addicts, we have inquired into the religious and social backgrounds and experiences of a group of narcotic addicts. It was observed that the subjects' parents were far less involved in religious practices than were a group of parents of nonaddicts. The addicts' fathers were found to be frequently absent from the home and uninvolved in the addicts' early religious training. The addicts came from broken homes and often their marriages also ended in divorce. The addicts, as compared to both their parents and the control subjects, were underachievers in both social and religious accomplishments.
Subject(s)
Opioid-Related Disorders , Religion , Black or African American , Family , Female , Humans , Male , Marriage , Paternal Deprivation , Socioeconomic Factors , Underachievement , White PeopleABSTRACT
A four-week double-blind comparison between lorazepam and placebo involving 60 patients with anxiety revealed that lorazepam in a mean dose of approximately 3 mg on a b.i.d. regimen is significantly and clinically more effective than placebo for almost all items of the Global, Hamilton, and 35-Item scales at nearly all evaluation periods. Moreover, lorazapem was associated with a 50% greater improvement rate than was placebo. Except for only one patient who was withdrawn from the study because of severe sedation, lorazepam was well tolerated and did not interact adversely with concomitant nonpsychoactive medication.
